Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
06 janv. 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin
15 déc. 2020 08h30 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham
07 déc. 2020 08h15 HE
|
Silo Pharma, Inc.
NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets
04 déc. 2020 16h52 HE
|
Silo Pharma, Inc.
NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco
16 nov. 2020 09h40 HE
|
Silo Pharma, Inc.
NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D....
Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications
12 nov. 2020 07h07 HE
|
Silo Pharma, Inc.
Each Provisional Patent Application Relates to Psilocybin NEW YORK , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on...
Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University
09 nov. 2020 07h15 HE
|
Silo Pharma, Inc.
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has...
Silo Pharma, Inc. (SILO) Announces Successful Uplisting To the OTCQB Venture Market
14 oct. 2020 10h06 HE
|
Silo Pharma, Inc.
To Begin Trading on the OTCQB Venture Market Under the Symbol “SILO” Today NEW YORK , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage...
Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides
13 oct. 2020 08h45 HE
|
Uppercut Brands, Inc.
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, announced that it...
Silo Pharma, Inc. Expands Board with Appointment of Dr. Kevin Muñoz MD; Announces Application to Uplist to OTCQB Market
06 oct. 2020 09h55 HE
|
Uppercut Brands, Inc.
NEW YORK , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO), which recently announced its transformation to a developmental stage biopharmaceutical company focused on the use of...